LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
47.59
+0.10 (0.21%)
Dec 20, 2024, 4:00 PM EST - Market closed
LivaNova Revenue
LivaNova had revenue of $318.12M in the quarter ending September 30, 2024, with 11.19% growth. This brings the company's revenue in the last twelve months to $1.24B, up 11.04% year-over-year. In the year 2023, LivaNova had annual revenue of $1.15B with 12.89% growth.
Revenue (ttm)
$1.24B
Revenue Growth
+11.04%
P/S Ratio
2.08
Revenue / Employee
$428,186
Employees
2,900
Market Cap
2.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.15B | 131.74M | 12.89% |
| Dec 31, 2022 | 1.02B | -13.56M | -1.31% |
| Dec 31, 2021 | 1.04B | 101.12M | 10.82% |
| Dec 31, 2020 | 934.24M | -149.93M | -13.83% |
| Dec 31, 2019 | 1.08B | -22.79M | -2.06% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Apr 24, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Surgery Partners | 2.99B |
| Concentra Group Holdings Parent | 1.88B |
| Neogen | 912.20M |
| HUTCHMED (China) | 610.81M |
| Catalyst Pharmaceuticals | 460.48M |
| Twist Bioscience | 312.97M |
| SpringWorks Therapeutics | 135.49M |
| Kymera Therapeutics | 87.56M |
LIVN News
- 3 days ago - RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression - Business Wire
- 16 days ago - LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting - Business Wire
- 5 weeks ago - LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences - Business Wire
- 5 weeks ago - LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints - Business Wire
- 7 weeks ago - LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - LivaNova Reports Third-Quarter 2024 Results - Business Wire
- 2 months ago - LivaNova: Economics Should Start Making Sustained Improvements - Seeking Alpha
- 2 months ago - LivaNova Appoints Susan Podlogar as a New Director - Business Wire